APA (7th ed.) Citation

DR, C., HR, K., MJ, A., JCH, Y., JY, H., MJ, H., . . . S, P. (2021). Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 16(12), 2091. https://doi.org/10.1016/j.jtho.2021.07.035

Chicago Style (17th ed.) Citation

DR, Camidge, et al. "Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 16, no. 12 (2021): 2091. https://doi.org/10.1016/j.jtho.2021.07.035.

MLA (9th ed.) Citation

DR, Camidge, et al. "Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 16, no. 12, 2021, p. 2091, https://doi.org/10.1016/j.jtho.2021.07.035.